哌甲酯与注意缺陷多动障碍儿童死亡率:基于人群的队列研究
该研究基于台湾全民健康保险研究数据库,纳入4-17岁ADHD儿童68 096例使用哌甲酯者与68 096例未使用者进行匹配队列分析。控制混杂因素后,哌甲酯使用与全因死亡率显著降低相关(AHR=0.81,95%CI 0.67-0.98,P=0.027),延迟使用与死亡率升高相关,使用时间越长死亡率越低。
要点
- 哌甲酯使用与ADHD儿童全因死亡率降低显著相关(AHR=0.81)。
- 延迟使用哌甲酯与死亡率升高相关(AHR=1.05)。
- 哌甲酯使用时间越长,死亡率越低(AHR=0.83)。
核心结论
- 在该队列研究中,哌甲酯使用与ADHD儿童全因死亡率降低相关,但不能完全排除未测量混杂。
研究设计与样本
- 基于台湾全民健康保险研究数据库的population-based队列研究,纳入4-17岁ADHD儿童68 096例使用哌甲酯者与68 096例未使用者,按年龄、性别和首次ADHD诊断年份匹配。
主要发现
- 哌甲酯组未调整的全因、自然、非自然和事故死亡率均低于对照组。
- 控制潜在混杂后,哌甲酯使用与全因死亡率显著降低相关(AHR=0.81,95%CI 0.67-0.98,P=0.027)。
- 延迟使用哌甲酯与死亡率升高相关(AHR=1.05,95%CI 1.01-1.09)。
- 哌甲酯使用时间越长与死亡率越低相关(AHR=0.83,95%CI 0.70-0.98)。
临床怎么用
- 临床可参考该人群研究结果,在ADHD儿童中评估哌甲酯使用时考虑其与死亡率降低的关联。
- 需注意该研究为观察性设计,不能完全排除未测量混杂,不可直接推断因果。
局限性
- 原文指出不能绝对排除未测量的混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Little is known about methylphenidate (MPH) use and mortality outcomes. AIMS: To investigate the association between MPH use and mortality among children with an attention-deficit hyperactivity disorder (ADHD) diagnosis. METHOD: This population-based cohort study analysed data from Taiwan's National Health Insurance Research Database (NHIRD). A total of 68 096 children and adolescents aged 4-17 years with an ADHD diagnosis and prescribed MPH between 2000 and 2010 were compared with 68 096 without an MPH prescription, matched on age, gender and year of first ADHD diagnosis. All participants were followed to death, migration, withdrawal from the National Health Insurance programme or 31 December 2013. MPH prescriptions were measured on a yearly basis during the study period, and the association between MPH use and mortality was analysed using a repeated-measures time-dependent Cox regression model. The outcome measures included all-cause, unnatural-cause (including suicide, accident and homicide) and natural-cause mortality, obtained from linkage to the National Mortality Register in Taiwan. RESULTS: The MPH group had lower unadjusted all-cause, natural-, unnatural- and accident-cause mortality than the comparison group. After controlling for potential confounders, MPH use was associated with a significantly lower all-cause mortality (adjusted hazard ratio AHR = 0.81, 95% CI 0.67-0.98, P = 0.027), delayed use of MPH was associated with higher mortality (AHR = 1.05, 95% CI 1.01-1.09) and longer MPH use was associated with lower mortality (AHR = 0.83, 95% CI 0.70-0.98). CONCLUSIONS: MPH use is associated with a reduced overall mortality in children with ADHD in this cohort study, but unmeasured confounding cannot be excluded absolutely.
引用
- Chen VC, Chan HL, Wu SI, et al. Methylphenidate and mortality in children with attention-deficit hyperactivity disorder: population-based cohort study. Br J Psychiatry. 2020. PMID: 32662370. doi:10.1192/bjp.2020.129
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。